BLAINJECTIONINJECTABLE
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TYRUKO (natalizumab-sztn) by Novartis is integrin receptor antagonists [moa]. Approved for multiple sclerosis, crohn's disease. First approved in 2023.
Mechanism of Action
Integrin Receptor Antagonists
Pharmacologic Class:
Integrin Receptor Antagonist
Indications (2)
Worked on TYRUKO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.